[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Outperforms Broader Market: What You Need to Know",
    "summary": "Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=513f73aeb49d1ae057273c8c2bb93181308c0ae34a1df2f7a0a8f4687fee9515",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761342303,
      "headline": "Moderna (MRNA) Outperforms Broader Market: What You Need to Know",
      "id": 137218729,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=513f73aeb49d1ae057273c8c2bb93181308c0ae34a1df2f7a0a8f4687fee9515"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine",
    "summary": "Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, following disappointing results from a Phase 3 clinical trial that did not meet its primary efficacy endpoint in seronegative women of childbearing age. This decision marks a setback for one of Moderna’s most advanced late-stage programs, highlighting the ongoing risks and volatility inherent in late-stage vaccine development. We’ll assess how discontinuing...",
    "url": "https://finnhub.io/api/news?id=b794f0a83db506ce433a946655e0d2eacb492cee5960a309d6fbc00618bba1e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761268532,
      "headline": "How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine",
      "id": 137218730,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, following disappointing results from a Phase 3 clinical trial that did not meet its primary efficacy endpoint in seronegative women of childbearing age. This decision marks a setback for one of Moderna’s most advanced late-stage programs, highlighting the ongoing risks and volatility inherent in late-stage vaccine development. We’ll assess how discontinuing...",
      "url": "https://finnhub.io/api/news?id=b794f0a83db506ce433a946655e0d2eacb492cee5960a309d6fbc00618bba1e5"
    }
  }
]